Pfizer and valneva complete recruitment for phase 3 valor trial for lyme disease vaccine candidate, vla15

Pfizer and valneva complete recruitment for phase 3 valor trial for lyme disease vaccine candidate, vla15 9,437* participants enrolled at sites across the u.s., europe and canada in areas where lyme disease is endemic trial conclusion expected by year-end 2025 pfizer aims to submit regulatory filings in the u.s. and europe in 2026 new york, ny, and saint-herblain (france), december 4, 2023 – pfizer inc. (nyse: pfe) and valneva se (nasdaq: valn; euronext paris: vla) today announced that they have completed recruitment for the phase 3 trial vaccine against lyme for outdoor recreationists (valor) (nct05477524) for lyme disease vaccine candidate vla15. the trial builds on previous positive phase 1 and 2 trial results and includes both adult and pediatric participants, with the aim to confirm the efficacy, safety, lot consistency, and immunogenicity of vla15.
VALN Ratings Summary
VALN Quant Ranking